<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282486</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0086</org_study_id>
    <nct_id>NCT04282486</nct_id>
  </id_info>
  <brief_title>Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease</brief_title>
  <acronym>M-HEMORRH'AGE</acronym>
  <official_title>Medication Exposure in Older Patients (AGEd &gt; 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The improvements observed in the care of patients with hemophilia or Willebrand disease have&#xD;
      led to an increase in their life expectancy, which today approaches that of the general&#xD;
      population. This increase in life expectancy leads in these patients to the development of&#xD;
      comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney&#xD;
      diseases) (e.g &quot;Franchini &amp; Mannuccio&quot;, BJH, 2009). The care of these comorbidities&#xD;
      represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy&#xD;
      is often associated.&#xD;
&#xD;
      Many studies about medication exposure and management in older patients were published but no&#xD;
      study was conducted to explore the medication management of older patients with hemophilia or&#xD;
      Willebrand disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">January 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list.</measure>
    <time_frame>At inclusion</time_frame>
    <description>A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted.</description>
  </primary_outcome>
  <enrollment type="Actual">142</enrollment>
  <condition>Hemophilia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <description>Primary objective: potentially inappropriate medication prevalence&#xD;
Secondary objective:&#xD;
Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index&#xD;
A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with hemophilia or Willebrand's disease (over 65) will have a telephone&#xD;
        interview in order to collect medication data from medical prescriptions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Community-dwelling patients over 65 years with hemophilia (A or B)&#xD;
&#xD;
          -  Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3,&#xD;
             rate &lt;30%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without phone number&#xD;
&#xD;
          -  Non French speaking patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HÃ´pital des Charpennes, Institut du Vieillissement</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Willebrand disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

